Medicine
Cystografin Dilute 54000 mg/300 mL injection
Cystografin Dilute 54000 mg/300 mL injection is a prescription medicine containing Diatrizoate for intravesical use, marketed by Bracco Diagnostics, with its source record on the US FDA register. It is available on request for export supply from India to licensed hospitals, importers and physicians.
Availability
Export supply from India to licensed buyers
Typical lead time
On request
Counted from payment and complete documents
Shipping
Ambient
Store at 20-25°C (68-77°F), protect from light.
Key facts
- Active ingredient (INN)
- Diatrizoate
- Brand
- Cystografin Dilute
- Strength
- 54000 mg/300 mL
- Dosage form
- Injection
- Route
- Intravesical
- Packs
- 10 bottles of 300 mL
- Marketing authorisation holder
- Bracco Diagnostics
- Manufacturer
- Bracco Diagnostics
- Origin register
- US FDA, United States
- Storage
- Store at 20-25°C (68-77°F), protect from light.
- Cold chain
- Not required on record
- Prescription status
- Prescription only
- Controlled substance
- Not recorded as controlled
- ATC code
- V08AA01 Diatrizoate
- HS code (indicative)
- 3004.90Indicative only. Your customs broker confirms the final tariff code.
- Marketing category
- marketed
- Marketed since
- 9 November 1982
- Identifiers
- DailyMed set ID e56882fa-4a30-43b1-bb6b-f7d4a4101c4eNDC 0270-1410Application NDA010040
Record updated 12 November 2026
Documents available
Documents that can be provided with this medicine. Your regulator may ask for more, and the quote lists the full set.
No document list is recorded for this medicine yet. Tell us which documents your regulator needs (for example a CoA, COPP or GMP certificate) when you request a quote.
Packs
| Pack | Code | Labeler | Marketed since |
|---|---|---|---|
| 10 bottle in 1 package / 300 mL in 1 bottle | 0270-1410-30 | Bracco Diagnostics | 9 November 1982 |
Status by register
Where this medicine is registered, from the source record and the regulator data we hold. Ask us about a country that is not listed.
| Register | Status | Source |
|---|---|---|
| US FDA | Listed, marketed | Source record for this pageChecked 12 November 2026 |
| US FDA | First approved 26 November 1954 | Drugs@FDA |
| EU (EMA) | Not recorded | — |
| India (CDSCO) | Not yet confirmed against CDSCO approval lists | — |
| United States | Registered | US FDA (NDC directory, openFDA)Checked 12 November 2026 |
Import route
Pick the destination country to see the legal import route, who applies and typical timelines, from our import guide for that country.
Import guides are available for 25 countries. Pick one to see its route summary.
BrazilColombiaEgyptEthiopiaGhanaIraqKazakhstanKenyaAll import guides
Other strengths and forms of Diatrizoate
Clinical summary
Diatrizoate is a radiographic contrast agent indicated for retrograde cystourethrography. It is available as oral solution, injection and oral liquid for rectal and intravenous use. MedsAcross supplies Diatrizoate for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
Read about DiatrizoateFor healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
Data sources
- DailyMed label record · Checked 12 November 2026
- Cystografin prescribing information (Bracco Diagnostics) · U.S. National Library of Medicine, DailyMed
Need Cystografin Dilute 54000 mg/300 mL injection for your hospital or patient?
Send one request with the destination country and quantity. We confirm availability, lead time and the documents your regulator needs.